Dakota Wealth Management Sells 393 Shares of Becton, Dickinson and Company (NYSE:BDX)

Dakota Wealth Management cut its position in Becton, Dickinson and Company (NYSE:BDX) by 1.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,711 shares of the medical instruments supplier’s stock after selling 393 shares during the quarter. Dakota Wealth Management’s holdings in Becton, Dickinson and Company were worth $5,606,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BDX. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $33,000. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares in the last quarter. Sound Income Strategies LLC raised its holdings in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $46,000. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,844 shares of company stock valued at $2,210,716 in the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI boosted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $238.05 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $248.42. The stock has a market capitalization of $69.04 billion, a P/E ratio of 40.08, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. The stock has a fifty day moving average of $227.31 and a 200-day moving average of $232.79.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the firm earned $3.42 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.75%. The ex-dividend date of this dividend was Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.